Biblio
Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial. Acta Haematol. 2019;141(2):111-118.
Soluble DNAM-1, as a Predictive Biomarker for Acute Graft-Versus-Host Disease. PLoS One. 2016;11(6):e0154173.